Annotation Detail

Information
Associated Genes
ROS1
Associated Variants
ROS1 REARRANGEMENT ROS1 REARRANGEMENT
Associated Disease
bronchiolo-alveolar adenocarcinoma
Source Database
CIViC Evidence
Description
Study describes a 31-year old male, never-smoker patient with advanced NSCLC with a ROS1 rearrangement. The patient was treated with crizotinib with marked response at 1 week and resolution of the tumor confirmed at 8 and 12 weeks via CT-scans. It was also demonstrated that crizotinib inhibits ROS1 phosphorylation in HEK 293 cells transfected with a CD14-ROS1 fusion gene, and crizotinib inhibited growth in the HCC78 cell line containing a ROS1 rearrangement to a similar degree as ALK-fusion positive cell lines.
Variant Origin
somatic
Variant Origin
Somatic
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/1443
Gene URL
https://civic.genome.wustl.edu/links/genes/4941
Variant URL
https://civic.genome.wustl.edu/links/variants/269
Rating
3
Evidence Type
Predictive
Disease
Bronchiolo-alveolar Adenocarcinoma
Evidence Direction
Supports
Drug
Crizotinib
Evidence Level
C
Clinical Significance
Sensitivity/Response
Pubmed
22215748
Drugs
Drug NameSensitivitySupported
CrizotinibSensitivitytrue